

Ablation of ceramide synthase 2 exacerbates dextran sodium sulphate-induced colitis in mice due to increased intestinal permeability

Ye-Ryung Kim ^{a, #}, Giora Volpert ^{b, #}, Kyong-Oh Shin ^c, So-Yeon Kim ^a, Sun-Hye Shin ^a,
Younghay Lee ^a, Sun Hee Sung ^d, Yong-Moon Lee ^c, Jung-Hyuck Ahn ^a, Yael Pewzner-Jung ^b, Woo-
Jae Park ^{e, *, *} 

^a Department of Biochemistry, College of Medicine, Ewha Womans University, Seoul, South Korea

^b Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel

^c College of Pharmacy, Chungbuk National University, Chongju, South Korea

^d Department of pathology, College of Medicine, Ewha Womans University, Seoul, South Korea

^e Department of Biochemistry, School of Medicine, Gachon University, Incheon, South Korea

Received: March 3, 2017; Accepted: May 2, 2017

Abstract

Ceramides mediate crucial cellular processes including cell death and inflammation and have recently been implicated in inflammatory bowel disease. Ceramides consist of a sphingoid long-chain base to which fatty acids of various length can be attached. We now investigate the effect of altering the ceramide acyl chain length on a mouse model of colitis. Ceramide synthase (CerS) 2 null mice, which lack very-long acyl chain ceramides with concomitant increase of long chain bases and C16-ceramides, were more susceptible to dextran sodium sulphate-induced colitis, and their survival rate was markedly decreased compared with that of wild-type littermates. Using mixed bone-marrow chimeric mice, we showed that the host environment is primarily responsible for intestinal barrier dysfunction and increased intestinal permeability. In the colon of CerS2 null mice, the expression of junctional adhesion molecule-A was markedly decreased and the phosphorylation of myosin light chain 2 was increased. *In vitro* experiments using Caco-2 cells also confirmed an important role of CerS2 in maintaining epithelial barrier function; CerS2-knockdown *via* CRISPR-Cas9 technology impaired barrier function. *In vivo* myriocin administration, which normalized long-chain bases and C16-ceramides of the colon of CerS2 null mice, increased intestinal permeability as measured by serum FITC-dextran levels, indicating that altered SLs including deficiency of very-long-chain ceramides are critical for epithelial barrier function. In conclusion, deficiency of CerS2 influences intestinal barrier function and the severity of experimental colitis and may represent a potential mechanism for inflammatory bowel disease pathogenesis.

Keywords: inflammatory bowel disease • ceramide • sphingolipid • acyl chains • dextran sodium sulphate

Introduction

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic, relapsing, inflammatory disorder of the gastrointestinal tract resulting in abdominal pain, diarrhoea, rectal bleeding and weight loss [1]. The prevalence of IBD is increasing worldwide, and it is considered an emerging global disease [2]. The aetiology of IBD involves a complex interaction between genetic

susceptibility and environmental risk factors (such as smoking, antibiotics, infection and oral contraceptives [2, 3]). However, none of these factors are clear determinants of IBD, with inconsistent observations reported among various studies. Therefore, additional studies are needed to better understand the aetiology and pathogenesis of IBD.

[#]Contributed equally to this manuscript

*Correspondence to: Joo-Won PARK
E-mail: joowon.park@ewha.ac.kr

Woo-Jae PARK
E-mail: ooze@gachon.ac.kr

Recently, sphingolipids (SLs) have emerged as targets for IBD therapy [1] *via* the roles they play in regulating immune cell function [4, 5] and mucosal integrity [6]. For example, dextran sodium sulphate (DSS)-induced experimental colitis is aggravated in animals lacking sphingosine 1-phosphate lyase, the enzyme that degrades sphingosine-1-phosphate (S1P), whereas the severity of experimental colitis is diminished upon genetic knockout of sphingosine kinase 1 [7]. In addition, the administration of S1P antagonists diminishes the severity of experimental murine colitis [4, 5, 8]. The role of S1P in IBD may be due to its regulation of CD4⁺ T cell function (such as migration and differentiation) or by activation of NF- κ B and STAT3 signalling [4, 5, 8, 9]. Ceramide is a key player in the pathway of SL metabolism, and ceramide regulates a plethora of cellular responses, including cell proliferation, apoptosis, differentiation and senescence [10]. Ceramide consists of a long-chain base linked by an amide bonds to a fatty acid; the length of the fatty acid varies significantly.

The ceramide acyl chains length is determined by a family of six ceramide synthases (CerS) [11]; CerS5/6 generates long-chain (C14–C16-) ceramides [11, 12], CerS1 generates C18-ceramide [13], CerS2 generates very-long chain (C22–C24-) ceramides [14]. The distinct role of ceramide depends on its acyl chain length, as shown in the various CerS-deficient mice which have been generated over the past few years [15]. For example, CerS1 deficiency results in Purkinje cell death and neuronal degeneration in the cerebellum [16, 17], whereas CerS2 deficiency results in a progressive demyelinating phenotype [18]. Similarly, CerS2 deficiency results in insulin resistance [19, 20], whereas CerS5 or CerS6 deficiency leads to improved glucose homeostasis [21, 22]. However, the role of ceramides with distinct acyl chain lengths in IBD has not been studied.

In this study, we used CerS2 null mouse to investigate the role of very-long chain ceramides in experimental colitis. In the colon of CerS2 null mice, levels of long-chain bases and C16-ceramides were elevated along with decrease of very-long chain ceramides. CerS2 null mice exhibited severe colitis upon DSS treatment, along with increased intestinal permeability, higher myosin light chain 2 (MLC2) phosphorylation and diminished levels of junctional adhesion molecule-A (JAM-A) in the colon. *In vitro* experiments using Caco-2 cells also indicated that CerS2 is crucial for maintaining epithelial barrier function. We suggest that CerS2, which regulates the levels of very-long chain ceramides, is important for intestinal barrier function, and altered acyl chain length of ceramides might be involved in the pathogenesis of IBD.

Materials and methods

Animals

CerS2-null mice have been described previously [23, 24]. Mice, 6–10 week of age, were housed under special pathogen-free conditions at 21–23°C and 51–54% humidity with a 12-hr light–dark cycle and were supplied with food and water *ad libitum*. All animals were treated in accordance with the Animal Care Guidelines of Ewha Womans

University and Weizmann Institute of Science, and the animal experiments and procedures were approved by the animal ethics committees at Ewha Womans University College of Medicine and the Weizmann Institute of Science.

DSS-induced colitis

To evaluate the severity and mortality by murine colitis, DSS was first administered orally to mice in drinking water (3%, w/v) for 5 days, followed by 5 days of plain water consumption (see Fig. 1). For all other experiments, 2% (w/v) DSS was mixed in drinking water, and mice were sacrificed after 7 days of DSS treatment. Bodyweights were assessed daily during experiments, and a disease activity index (DAI) score was calculated to evaluate the clinical progression of colitis. The DAI is a combined score of weight loss compared to initial weight (0, no loss; 1, 1–5%; 2, 5–10%; 3, 10–20%; and 4, >20% loss), stool consistency (0, normal; 2, loose stool; and 4, diarrhoea) and rectal bleeding (0, no blood; 1, Hemoccult positive; 2, Hemoccult positive and visual pellet bleeding; and 4, gross bleeding, blood around anus) [25].

Cell culture and generation of CerS2-knockdown cells

Caco-2 cells were cultured in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, USA) supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin (Hyclone).

The *CERS2* gene was deleted from Caco-2 cells using the CRISPR/Cas9 genome editing system and the GeneArt CRISPR nuclease vector with a CD4 enrichment kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol [26]. Briefly, target-specific oligonucleotides (top strand, 5'-GCCGATCTAGAAGACCGAGAGTTTT-3'; and bottom strand, 5'-GATCGGTCTTCTAGATCGGTCGGTG-3') were synthesized by Macrogen (Seoul, South Korea), and a double-stranded oligonucleotide with compatible ends was cloned into the GeneArt CRISPR nuclease vector. The presence of the double-stranded oligonucleotide insert was confirmed by sequencing. Caco-2 cells were transfected with the CRISPR/Cas9 vector using Metafectene (Biotex Laboratories, Edmonton, Alberta, Canada) according to the manufacturer's instructions. Transfected cells were screened and sorted using the CD4⁺ T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).

Transepithelial electrical resistance

A transepithelial electrical resistance (TEER) assay was performed as reported previously [27]. Briefly, Caco-2 cells were seeded on tissue culture polycarbonate membrane filters (pore size, 0.4 μ m) in 24-well transwell plates at a seeding density of 2×10^5 cells/cm² (Corning, Inc., Acton, MA, USA). The culture medium was added to the upper and lower chambers and was changed every second day. The cells were maintained to differentiate for 14 days after seeding with monitoring of TEER. Prior to TEER measurement, the standard medium was substituted with foetal bovine serum-free culture medium. The electrical resistance was measured using a Millicell ERS meter (Millipore, Bedford, MA, USA) and calculated as Ω cm².




Fig. 1 DSS-induced colitis is exacerbated upon CerS2 deficiency. To induce colitis, mice were exposed to 3% (w/v) DSS in the drinking water for 5 days followed by normal plain water for another 5 days. For controls, normal plain water was consumed for 10 days. **(A)** Bodyweight changes and **(B)** survival curves of WT and CerS2 null mice. **(C)** Disease activity index values, **(D)** colon lengths, **(E)** representative colon pictures, **(F)** histological scores and **(G)** H & E-stained colonic sections of mice. The scale bar indicates 200 μm. Data are means ± S.E.M. ($n = 5$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Statistical analyses

All the experiments were repeated at least three times independently, and values are given as means \pm S.E.M. Statistical significance was calculated using Student's *t*-tests, and *P* values of <0.05 were considered significant.

Details of other experiments are described in the supplementary information.

Results

CerS2 deficiency exacerbates DSS-induced colitis

To investigate the role of the SL acyl chain length on IBD, colitis was induced by treating CerS2 null mice with DSS, a chemical irritant, due to its simplicity and many similarities with human ulcerative colitis [28]. DSS was orally administered to mice in drinking water (3%, w/v) for 5 days, followed by 5 days of plain water consumption. Compared to WT controls, CerS2 null mice displayed aggravated colitis as manifested by greater bodyweight loss and worse survival rates (Fig. 1A and B). Disease activity index (DAI) values calculated by summing the scores reflecting weight loss, stool consistency and rectal bleeding were significantly elevated in CerS2 null mice (Fig. 1C). In addition, the length of the colons after DSS treatment was shorter in CerS2 null mice (Fig. 1D and E). The colons of untreated CerS2 null mice had a normal histological appearance, but higher scores of colonic epithelial damage and inflammatory infiltration were observed after DSS treatment (Fig. 1F and G). Similar results with no mortality were obtained by administration of 2% (w/v) DSS mixed in drinking water for 7 days (Fig. S1). Although the increase in blood leucocyte levels upon DSS treatment was similar in CerS2 null and WT mice, a greater increase in levels of neutrophils was observed in CerS2 null mice (Fig. S2). Together, these findings suggest that CerS2 deficiency exacerbates experimental colitis in mice.

Ceramide acyl chain length in the colon of CerS2 null mice

Significant changes were detected in SL levels in the colon of CerS2 null mice. Similar to the SL composition in liver reported earlier [23], levels of long-chain bases, including sphingosine and sphinganine, and C16-ceramides were significantly elevated with concomitant decrease of C22-C24 ceramides in the colon of CerS2 null mice (Fig. 2A and B), and total ceramide levels were not different between CerS2 null and WT mice (Fig. 2B), which is also similar to the liver [23]. However, DSS administration in both WT and CerS2 null mice increased total ceramide levels as well as levels of long chain bases, which suggests activation of the *de novo* SL synthesis pathway (Fig. 2A and B). The elevated levels of total ceramides after DSS

treatment were mainly derived from C16-ceramide (Fig. 2B). Scheme of SL metabolism and altered SL levels in the colon of CerS2 null mice were described (Fig. 2C).

The host environment plays a major role in the development of colitis in CerS2 null mice

As DSS-induced colitis is driven by innate immune cells [29, 30], we generated BM chimeras in which WT or CerS2 null mice received either CerS2 deficient or WT BM to examine whether any cells of haematopoietic origin are involved in the development of colitis in CerS2 null mice. We reduced the amount of DSS administered to the mice from 3% to 2% (w/v) to reduce mortality, and DSS was administered in the drinking water for 7 days to induce acute colitis in BM chimeric mice. Irrespective of the reconstituted BM types, CerS2 null recipients lost more weight, had significantly higher DAI scores and showed shorter colon lengths than WT recipients (Fig. 3A). We further generated mixed BM chimeras in which WT or CerS2 null mice received 50% CerS2 null and 50% WT BM. Similar to the data from BM chimeric mice, CerS2 null recipients with mixed BM also showed severe colitis (Fig. 3B). Although we cannot exclude completely the role of the immune system in this model, these data suggest that host environment (including epithelial cells in the colon) likely plays a major role under these conditions.

Thus, we next evaluated the proliferation and death of non-haematopoietic cells in the colon after DSS administration. TUNEL staining indicated that DSS treatment increased apoptosis in the colon of CerS2 null mice (Fig. 4), whereas cell proliferation was unaffected (Fig. 5A). Neutrophil infiltration, as determined by myeloperoxidase assay [31], was increased in the colon of CerS2 null mice treated with DSS (Fig. 5B). As defective epithelial barrier function has been implicated in IBD [32], we then evaluated intestinal permeability using FITC-dextran (Fig. 6A and B). Compared to WT controls, blood levels of orally administered 4 or 40 kD FITC-dextran were increased significantly in CerS2 null mice with and without DSS treatment, indicating increased intestinal permeability in CerS2 null mice under both basal and inflammatory states.

Decreased JAM-A expression in the colon of CerS2 null mice

Mucin dysfunction [33, 34] and JAM-A deficiency [35, 36] have been shown to cause increased intestinal permeability, especially under basal conditions, with an enhanced susceptibility to experimental colitis. Thus, we evaluated mucin production in CerS2 null mice. The mucus blanket overlying the intestinal epithelium consists of an inner stratified layer that tightly adheres to epithelial cells and an outer unattached layer [33]. These two layers are organized into a net-like polymer around mucin 2, the most abundant mucin protein, which is heavily glycosylated and secreted by




Fig. 2 Effects of CerS2 deletion on colon sphingolipid levels upon DSS administration. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). Long-chain bases (A) and ceramides (B) were measured by ESI-MS/MS. The x axis of the right panel in B shows the acyl chain lengths of the individual ceramide species. Results are expressed as means \pm S.E.M. ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. (C) Scheme of SL metabolism and altered SL levels in the colon of CerS2 null mice were described.




Fig. 3 CerS2-deficient host environments influence colitis severity in CerS2 null mice. Acute colitis was induced with 2% DSS in the drinking water for 7 days in **(A)** BM chimeras generated by injecting lethally irradiated WT or CerS2 null mice with 100% WT or CerS2 null BM cells and **(B)** mixed BM chimeras generated by injecting lethally irradiated WT or CerS2 null mice with 50% WT + 50% CerS2 null BM cells. Bodyweight changes were monitored during the experiment, and disease activity index scores and colon length were determined. Data are means \pm S.E.M. ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Mix, 50% WT + 50% CerS2 null BM cells.




Fig. 4 Increased apoptosis in CerS2 null mice with colitis. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). TUNEL-positive (green) cells indicating apoptotic cells were examined using immunofluorescence (left panel) and quantified using Image J (right panel); nuclei are counterstained with DAPI (blue) (400 \times magnification). Results are means \pm S.E.M. ($n = 4$). * $P < 0.05$. Images are typical of four independent experiments.

goblet cells [33]. Mucin can be detected by PAS and alcian blue staining (PAS detects neutral carbohydrates, whereas alcian blue recognizes acidic carbohydrates that represent sialylated,

fucosylated or sulphated sugars [34]). However, PAS and alcian blue staining were normal in the colon of CerS2 null mice (Fig. S3), indicating normal mucin production.




Fig. 5 Increased myeloperoxidase activity in CerS2 null mice with colitis. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). **(A)** Ki-67-positive cells undergoing proliferation are stained DAB as a chromogen (200× magnification). Arrows indicated Ki-67-positive cells. **(B)** Myeloperoxidase (MPO) enzymatic activity was determined as an index of neutrophil infiltration into injured colon tissue. Results are means ± S.E.M. ($n = 5$). * $P < 0.05$, ** $P < 0.01$. Images are typical of three independent experiments.




Fig. 6 Intestinal permeability is increased in CerS2 null mice. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). Mice were orally administered 4 **(A)** or 40 **(B)** kDa FITC-dextran (0.6 g/kg bodyweight) in 0.1 ml phosphate-buffered saline and fluorescence intensity in the serum was evaluated by spectrophotometry after 4 hrs. Results are expressed as means ± S.E.M. ($n = 5$). * $P < 0.05$, ** $P < 0.01$.

We next evaluated the expression of components of epithelial tight junctions. The epithelial cells lining the gastrointestinal tract are connected *via* desmosomes and gap junctions, as well as tight and adherens junctions [37, 38], which comprise the apical junctional complex that is generally believed to play an essential role in maintaining the epithelial barrier [37]. In apical junctional complexes in CerS2 null mice, the expression of JAM-A, which has been implicated in the regulation of barrier function and leucocyte migration [35], was significantly reduced with and without DSS treatment compared to WT mice (Fig. 7A and B). Although basal levels of occludin expression were not different between the colon of CerS2 null and WT mice, the expression decreased

dramatically in CerS2 null mice treated with DSS (Fig. 7A). The levels of other junctional proteins, such as ZO-1, E-cadherin and claudins, were not altered significantly in CerS2 null mice compared to WT mice (Fig. 7A, Fig.S4).

Increased MLC2 phosphorylation in the colon of CerS2 null mice

Myosin light chain kinase (MLCK)-induced contractility of the perijunctional actomyosin ring, that encircles the enterocyte at the level of the tight junction through numerous smaller proteins




Fig. 7 JAM-A protein expression is diminished in the colon of CerS2 null mice. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). **(A)** Representative Western blots of apical junctional complex proteins (upper panels) and quantification (lower panels) ($n = 5$) of JAM-A and occludin in colon. $*P < 0.05$. **(B)** JAM-A expression (green) in the colon upon DSS treatment in WT and CerS2 null mice was examined using immunofluorescence; nuclei are counterstained with DAPI (blue) (200 \times magnification). ZO-1, zonula occludens-1.

[39], is considered another important mechanism underlying disruption of the epithelial barrier [37]. Thus, we evaluated the expression of MLCK in colons of DSS-treated and control mice. Protein expression was not altered in CerS2 null mice; however, MLC2 phosphorylation was increased significantly in the colon of CerS2 null mice (Fig. 8), suggesting that increased contraction of the actomyosin belt may contribute to the elevated intestinal permeability in these mice.

CerS2 knockdown Caco-2 cells display impaired barrier function

To confirm an important role of CerS2 in regulating intestinal barrier function, we used Caco-2 cells, a human colon epithelial cell line, which differentiate spontaneously into a monolayer of polarized cells coupled by tight junctions after 2–3 week [40]. We generated CerS2-knockdown Caco-2 cells using CRISPR-Cas9 (Fig. 9A) and measured transepithelial electrical resistance (TEER) upon spontaneous differentiation. TEER is a widely accepted quantitative technique for measuring the integrity of tight junction dynamics in cultured endothelial and epithelial monolayers [41]. Similar to the increased intestinal permeability in CerS2 null mice, CerS2 knockdown Caco-2 cells displayed lower TEER levels during differentiation (Fig. 9B), confirming an important role of CerS2 in maintaining the integrity of the cellular barrier. In addition, CerS2 knockdown Caco-2 cells also exhibited increased permeability to 4 and 40 kD FITC-Dextran (Fig. 9C), as well as increased MLC2 phosphorylation (Fig. 9D). However, the levels of JAM-A were not altered by CerS2 knockdown in these cells (Fig. 9D), suggesting that JAM-A expression is not directly affected by CerS2 modulation. SL levels in CerS2 knockdown Caco-2 cells were altered similarly with the colon of CerS2 null mice (Fig. S5); levels of sphinganine and C16-ceramides were increased with decrease of C22-C24 ceramides.




Fig. 8 MLC-2 phosphorylation is increased in colons of CerS2 null mice. Mice were exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis or normal plain water (control). Representative Western blots of myosin light chain kinase (MLCK), phospho-myosin light chain 2 (P-MLC2), total-MLC2 (T-MLC2) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Data represent three independent experiments.

SL homeostasis is important for cellular barrier integrity

Finally, we explored whether decreasing the levels of long-chain bases and C16-ceramide restores barrier integrity in colons of CerS2 null mice using oral fumonisins B1 and myriocin administration. Treatment of myriocin, a serine palmitoyltransferase inhibitor, decreased levels of SLs including long-chain bases and C16-ceramide as reported previously [42] (Fig. 10A and B). Treatment of fumonisins B1, a CerS inhibitor, led to elevation of long-chain bases and decrease of ceramides including C16-ceramide in accordance with previous reports [43, 44] (Fig. 10A and B). Myriocin administration in CerS2 null mice normalized the elevated levels of long-chain bases and C16-ceramides (Fig. 10A and B). Fumonisin B1 treatment in CerS2 null mice only normalized the elevated levels of C16-ceramides, but not the levels of long-chain bases (Fig. 10A and B). Both treatments aggravated the intestinal permeability of CerS2 null mice as measured by serum FITC-dextran levels (Fig. 11A) and diminished the colon length of CerS2 null mice upon DSS administration (Fig. 11B), suggesting that elevated levels of long-chain bases and C16-ceramide themselves are not mainly responsible for the increased intestinal permeability in CerS2 null mice, and rather altered SL levels including reduction of C22-C24-ceramides may indeed play a crucial role in increased intestinal permeability of CerS2 null mice. However, fumonisins B1 administration increased intestinal permeability of CerS2 null mice much higher than myriocin administration, suggesting an aggravating role of long-chain bases in intestinal permeability of CerS2 null mice. Although both myriocin and fumonisins B1 treatments in WT mice diminished total ceramide levels significantly, the levels of C22-C24 ceramides in WT were still higher than that in CerS2 null mice (Fig. 10B). In addition, both treatments did not affect the intestinal permeability of WT mice as measured by serum FITC-dextran levels (Fig. 11A) and the colon length of WT mice upon DSS administration (Fig. 11B), implicating that partially diminished levels of C22-C24 ceramides by chemical administration are not sufficient to aggravate colitis symptoms.

Discussion

The results from this study demonstrate that CerS2, which regulates levels of C22–C24-SLs, plays an important role in maintaining intestinal epithelial barrier function. CerS2 null mice displayed increased intestinal permeability and exacerbated colitis induced by DSS. Although the pathogenesis of IBD remains unclear, increasing evidence suggests that intestinal permeability plays a crucial role, and defective epithelial barrier function has been reported to predict relapse during clinical remission [45]. Thus, elucidating the mechanisms for defects in barrier function and permeability has a great potential for defining IBD pathogenesis and uncovering novel therapeutic targets.

Important roles of ceramides in maintaining intestinal barrier function have been suggested by several studies. For example, the accumulation of ceramide at the sites of cell/cell-contact induced by




Fig. 9 CerS2 deficiency leads to impaired cellular barrier function. CerS2-knockdown Caco-2 cells. **(A)** Representative Western blots of CerS2 and GAPDH. **(B)** TEER values from Caco-2 cells were measured during spontaneous differentiation. **(C)** Permeability of differentiated Caco-2 cells was analysed using 4 kDa (left panel) and 40 kDa (right panel) FITC-dextran. **(D)** Representative Western blots of MLC2 phosphorylation and JAM-A. Results are expressed as means \pm S.E.M. ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Data represents three independent experiments.




Fig. 10 Effects of myriocin and fumonisins B1 administrations on colon sphingolipid levels. Mice were orally administered fumonisins B1 (1.5 mg/kg/day) or myriocin (0.5 mg/kg/day) for 10 days. Long-chain bases **(A)** and ceramides **(B)** were measured by ESI-MS/MS. The x axis of the right panel in **B** shows the acyl chain lengths of the individual ceramide species. Results are expressed as means \pm S.E.M. ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Con, control; Myri, myriocin; Fumo, fumonisins B1.

exogenous sphingomyelinase increases intestinal permeability [46], and blocking ceramide generation using a sphingomyelinase inhibitor alleviates murine colitis [47]. Although a specific increase of C18:

1-ceramides *via* alkaline ceramidase 3 deficiency exacerbates inflammation in experimental colitis [48], distinct roles of ceramides with other acyl chain lengths in IBD have not been




Fig. 11 Administrations of fumonisins B1 and myriocin in *Cers2* null mice increase intestinal permeability. Mice were orally administered fumonisins B1 (1.5 mg/kg/day) or myriocin (0.5 mg/kg/day) for 3 days and then exposed to 2% (w/v) DSS in the drinking water for 7 days to induce colitis with coadministration with fumonisins B1 or myriocin. **(A)** Mice were orally administered 4 kDa FITC-dextran (0.6 g/kg bodyweight) in 0.1 ml phosphate-buffered saline, and fluorescence intensity in serum was then examined by spectrophotometry after 4 hrs. **(B)** Colon lengths of mice were measured. Results are expressed as means \pm S.E.M. ($n = 4$). * $P < 0.05$, ** $P < 0.01$. Con, control; Myri, myriocin; Fumo, fumonisins B1.

explored. *CerS2* generates C22-C24 ceramides distinctly, and lack of *CerS2* leads to a decrease of C22-C24 ceramides with an increase of C16-ceramides and long-chain bases [23]. As increased levels of ceramide have been reported to be associated with increased intestinal permeability [46], elevated levels of C16-ceramides may cause increased intestinal permeability of *CerS2* null mice. However, myriocin treatment which normalized levels of C16-ceramides and long-chain bases in the colon of *CerS2* null mice even elevated intestinal permeability. The accumulation of ceramide in Caco-2 cells by exogenous sphingomyelinase leads to an altered lipid composition of microdomain [46]. Recently, we also reported that the acyl chain length of SLs determines the biophysical properties of membranes and affects lipid raft microdomain formation and insulin signalling in the liver [19]. In addition, tight junction proteins including ZO-1, occludin and JAM-A are localized in lipid rafts, and lipid raft alteration induced by

cholesterol depletion disrupts barrier function by altering the distribution of tight-junction proteins [49]. Therefore, altered membrane properties including lipid raft microdomain either by deficiency of *CerS2* or by treatment of exogenous sphingomyelinase [46] may affect tight junction function in the intestine. Furthermore, membranes from *CerS2* null mice exhibited a higher membrane fluidity [23] and increased membrane fluidity may influence intestinal permeability directly as modulation of permeability *via* altered membrane fluidity has been suggested by several studies [50, 51].

Both the colon of *CerS2* null mice and *CerS2* knockdown Caco-2 cells displayed increased MLC2 phosphorylation, implicating *CerS2* in apical actomyosin contraction. As MLCK protein expression was not increased in the colon of *CerS2* null mice, *CerS2* depletion may lead to increased MLC2 phosphorylation possibly *via* regulating MLCK or MLC2 phosphatase activity. Similar to *CerS2*

null mice, transgenic mice expressing constantly active MLCK also showed increased MLC2 phosphorylation with elevated intestinal permeability, but no overt histologic signs of intestinal inflammation [52]. Consistent with the presence of increased permeability in some healthy first-degree relatives of Crohn's disease patients [53], increased intestinal permeability of CerS2 null mice was also insufficient to cause spontaneous colitis or histologic signs of intestinal inflammation in the absence of other stimuli. Phosphorylation of MLC2 leads to tight junction rearrangement, and reduction of intestinal barrier function, and CD4⁺CD45RB^{hi} adoptive transfer into transgenic mice expressing constantly active MLCK resulted in a much more severe colitis compared with control mice [52]. In addition, the localization of tight junction proteins in the transgenic mice expressing constantly active MLCK was also intact similar to that in CerS2 null mice [52].

As with CerS2 null mice, mice deficient in JAM-A exhibit increased basal intestinal permeability with normal epithelial architecture [35]. JAM-A regulates apical actomyosin contraction, and deficiencies lead to enhanced MLC2 phosphorylation [36]. However, unlike in mice with JAM-A deficiency [35], CerS2 null mice did not show increased epithelial proliferation and formation of large lymphoid aggregates. A possible explanation for this is that JAM-A was only partially decreased in the colons of CerS2 null mice. Furthermore, experiments with CerS2 knockdown Caco-2 cells indicated that JAM-A is not directly regulated by CerS2 expression, and thus, the diminished JAM-A protein levels in the colons of CerS2 null mice may not be directly related with CerS2 deficiency.

Fumonisin B1 elevates levels of long-chain bases and decreases levels of all kinds of ceramides and their derivatives [43], and relatively high doses (>50 μ M) have been reported to cause impaired barrier function in porcine intestinal epithelial cells [54]. Similarly, fumonisin B1 administration dramatically increased intestinal permeability in CerS2 null mice. However, both fumonisin B1 and myriocin administration cause increased intestinal permeability of FITC-dextran only in CerS2 null mice but not in WT mice, suggesting that altered long-chain bases or reduced levels of ceramides and their derivatives by themselves are insufficient to impair pre-formed epithelial barrier function *in vivo*, but may exacerbate pre-existing barrier dysfunction. In other words, decreased levels of ceramides (including very-long-chain ceramides by CerS2 deficiency) may be able to inhibit epithelial barrier formation of complex protein-protein networks that mechanically link adjacent cells and seal the intercellular space, but may be insufficient to disrupt pre-formed intestinal barrier function [55]. Otherwise, the degree of reduction in the levels of very long-chain ceramides may determine epithelial barrier function considering that both myriocin and fumonisin B1 treatments only partially diminished very long-chain ceramides. The different roles of ceramides according to the degree of reduction were also reported previously [15, 20]. CerS2 haplodeficiency partially decreased very long-chain ceramides, but the phenotype of CerS2 haplodeficiency on triacylglycerol accumulation was opposite with that of CerS2 total deficiency [20, 56]. Still, the precise effects of long-chain

bases and specific ceramides in intestinal barrier function should be further elucidated in the future, as systemic administration of fumonisin B1 and myriocin can affect many organs other than colon.

In conclusion, our data suggest that CerS2 and the levels of very long-chain ceramides are crucial for intestinal barrier function. The results of this study also suggest that SL homeostasis including altered acyl chain composition may be involved in the pathogenesis of IBD by regulating intestinal permeability, and the development of techniques modulating acyl chain lengths of ceramides might be applied as a novel therapy for IBD.

Acknowledgements

This work was supported by grants from the Health Technology R&D Project (H114C2445) of the Ministry of Health and Welfare, Republic of Korea, by intramural research promotion grants from Ewha Womans University School of Medicine and by grant from the Israel Science foundation (grant number 1728/15). We thank Dr. Kwon Oran (Ewha Womans University, Department of Nutritional Science and Food Management, Seoul, South Korea) for supplying Caco-2 cells. A.H. Futerman is the Joseph Meyerhoff Professor of Biochemistry at the Weizmann Institute of Science.

Conflicts of interest

None.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Appendix S1 Materials and methods

Fig. S1 DSS-induced colitis is exacerbated upon CerS2 deficiency

Fig. S2 Haematological analysis of white blood cells in WT and CerS2 null mice

Fig. S3 Mucin production and mucin 2 expression are not altered in colons of CerS2-null mice

Fig. S4 Claudin expression is not altered in colons of CerS2 null mice

Fig. S5 Effects of CerS2 knockdown on sphingolipid levels in CaCo-2 cells

Table S1 Primers used for real time PCR

References

1. **Coskun M, Vermeire S, Nielsen OH.** Novel targeted therapies for inflammatory bowel disease. *Trends Pharmacol Sci.* 2017; 38: 127–42.
2. **M'Koma AE.** Inflammatory bowel disease: an expanding global health problem. *Clin Med Insights Gastroenterol.* 2013; 6: 33–47.
3. **Molodecky NA, Kaplan GG.** Environmental risk factors for inflammatory bowel disease. *Gastroenterol Hepatol (NY).* 2010; 6: 339–46.
4. **Daniel C, Sartory N, Zahn N, et al.** FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4 + CD25 + regulatory T cells. *J Immunol.* 2007; 178: 2458–68.
5. **Daniel C, Sartory NA, Zahn N, et al.** FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. *Mol Immunol.* 2007; 44: 3305–16.
6. **Huang WC, Liang J, Nagahashi M, et al.** Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. *FASEB J.* 2016; 30: 2945–58.
7. **Degagne E, Pandurangan A, Bandhuvula P, et al.** Sphingosine-1-phosphate lyase down-regulation promotes colon carcinogenesis through STAT3-activated microRNAs. *J Clin Invest.* 2014; 124: 5368–84.
8. **Liang J, Nagahashi M, Kim EY, et al.** Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. *Cancer Cell.* 2013; 23: 107–20.
9. **Sanada Y, Mizushima T, Kai Y, et al.** Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. *PLoS One.* 2011; 6: e23933.
10. **Kitatani K, Idkowiak-Baldys J, Hannun YA.** The sphingolipid salvage pathway in ceramide metabolism and signaling. *Cell Signal.* 2008; 20: 1010–8.
11. **Levy M, Futerman AH.** Mammalian ceramide synthases. *IUBMB Life.* 2010; 62: 347–56.
12. **Mizutani Y, Kihara A, Igarashi Y.** Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. *Biochem J.* 2005; 390: 263–71.
13. **Venkataraman K, Riebeling C, Bodenne J, et al.** Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. *J Biol Chem.* 2002; 277: 35642–9.
14. **Laviad EL, Albee L, Pankova-Kholmyansky I, et al.** Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. *J Biol Chem.* 2008; 283: 5677–84.
15. **Park WJ, Park JW.** The effect of altered sphingolipid acyl chain length on various disease models. *Biol Chem.* 2015; 396: 693–705.
16. **Zhao L, Spassieva SD, Jucius TJ, et al.** A deficiency of ceramide biosynthesis causes cerebellar purkinje cell neurodegeneration and lipofuscin accumulation. *PLoS Genet.* 2011; 7: e1002063.
17. **Ginkel C, Hartmann D, vom Dorp K, et al.** Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes. *J Biol Chem.* 2012; 287: 41888–902.
18. **Ben-David O, Pewzner-Jung Y, Brenner O, et al.** Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. *J Biol Chem.* 2011; 286: 30022–33.
19. **Park JW, Park WJ, Kuperman Y, et al.** Ablation of very long acyl chain sphingolipids causes hepatic insulin resistance in mice due to altered detergent-resistant membranes. *Hepatology.* 2013; 57: 525–32.
20. **Raichur S, Wang ST, Chan PW, et al.** CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. *Cell Metab.* 2014; 20: 687–95.
21. **Gosejacob D, Jager PS, Vom Dorp K, et al.** Ceramide Synthase 5 Is Essential to Maintain C16:0-Ceramide Pools and Contributes to the Development of Diet-induced Obesity. *J Biol Chem.* 2016; 291: 6989–7003.
22. **Turpin SM, Nicholls HT, Willmes DM, et al.** Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. *Cell Metab.* 2014; 20: 678–86.
23. **Pewzner-Jung Y, Park H, Laviad EL, et al.** A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. *J Biol Chem.* 2010; 285: 10902–10.
24. **Pewzner-Jung Y, Brenner O, Braun S, et al.** A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy. *J Biol Chem.* 2010; 285: 10911–23.
25. **Kim JJ, Shajib MS, Manocha MM, et al.** Investigating intestinal inflammation in DSS-induced model of IBD. *J Vis Exp.* 2012; 60: 3678.
26. **Tsukamoto K, Ozeki C, Kohda T, et al.** CRISPR/Cas9-Mediated Genomic Deletion of the Beta-1, 4 N-acetylgalactosaminyltransferase 1 Gene in Murine P19 Embryonal Carcinoma Cells Results in Low Sensitivity to Botulinum Neurotoxin Type C. *PLoS One.* 2015; 10: e0132363.
27. **Kowapradit J, Opanasopit P, Ngawhirunpat T, et al.** *In vitro* permeability enhancement in intestinal epithelial cells (Caco-2) monolayer of water soluble quaternary ammonium chitosan derivatives. *AAPS PharmSciTech.* 2010; 11: 497–508.
28. **Chassaing B, Aitken JD, Malleshappa M, et al.** Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr Protoc Immunol.* 2014; 104: Unit 15. 25.
29. **Berndt BE, Zhang M, Chen GH, et al.** The role of dendritic cells in the development of acute dextran sulfate sodium colitis. *J Immunol.* 2007; 179: 6255–62.
30. **Lin Y, Yang X, Yue W, et al.** Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. *Cell Mol Immunol.* 2014; 11: 355–66.
31. **Laroui H, Ingersoll SA, Liu HC, et al.** Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. *PLoS One.* 2012; 7: e32084.
32. **Hollander D.** Crohn's disease—a permeability disorder of the tight junction? *Gut.* 1988; 29: 1621–4.
33. **Wei X, Yang Z, Rey FE, et al.** Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2. *Cell Host Microbe.* 2012; 11: 140–52.
34. **An G, Wei B, Xia B, et al.** Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. *J Exp Med.* 2007; 204: 1417–29.
35. **Laukoetter MG, Nava P, Lee WY, et al.** JAM-A regulates permeability and inflammation in the intestine *in vivo*. *J Exp Med.* 2007; 204: 3067–76.
36. **Monteiro AC, Sumagin R, Rankin CR, et al.** JAM-A associates with ZO-2, afadin, and PDZ-GEF1 to activate Rap2c and regulate epithelial barrier function. *Mol Biol Cell.* 2013; 24: 2849–60.

37. **Ivanov AI, Parkos CA, Nusrat A.** Cytoskeletal regulation of epithelial barrier function during inflammation. *Am J Pathol.* 2010; 177: 512–24.
38. **Tsukita S, Furuse M, Itoh M.** Multifunctional strands in tight junctions. *Nat Rev Mol Cell Biol.* 2001; 2: 285–93.
39. **Arrieta MC, Bistritz L, Meddings JB.** Alterations in intestinal permeability. *Gut.* 2006; 55: 1512–20.
40. **Ferruzza S, Rossi C, Scarino ML, et al.** A protocol for differentiation of human intestinal Caco-2 cells in asymmetric serum-containing medium. *Toxicol In Vitro.* 2012; 26: 1252–5.
41. **Srinivasan B, Kollu AR, Esch MB, et al.** TEER measurement techniques for *in vitro* barrier model systems. *J Lab Autom.* 2015; 20: 107–26.
42. **Hojjati MR, Li Z, Zhou H, et al.** Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. *J Biol Chem.* 2005; 280: 10284–9.
43. **Park WJ, Park JW, Erez-Roman R, et al.** Protection of a ceramide synthase 2 null mouse from drug-induced liver injury: role of gap junction dysfunction and connexin 32 mislocalization. *J Biol Chem.* 2013; 288: 30904–16.
44. **Enongene EN, Sharma RP, Bhandari N, et al.** Disruption of sphingolipid metabolism in small intestines, liver and kidney of mice dosed subcutaneously with fumonisin B(1). *Food Chem Toxicol.* 2000; 38: 793–9.
45. **Michielan A, D’Inca R.** Intestinal Permeability in Inflammatory Bowel Disease: pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. *Mediators Inflamm.* 2015; 2015: 628157.
46. **Bock J, Liebisch G, Schweimer J, et al.** Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. *World J Gastroenterol.* 2007; 13: 5217–25.
47. **Sakata A, Ochiai T, Shimeno H, et al.** Acid sphingomyelinase inhibition suppresses lipopolysaccharide-mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice. *Immunology.* 2007; 122: 54–64.
48. **Wang K, Xu R, Snider AJ, et al.** Alkaline ceramidase 3 deficiency aggravates colitis and colitis-associated tumorigenesis in mice by hyperactivating the innate immune system. *Cell Death Dis.* 2016; 7: e2124.
49. **Lambert D, O’Neill CA, Padfield PJ.** Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight-junction proteins. *Biochem J.* 2005; 387: 553–60.
50. **Khajuria A, Thusu N, Zutshi U.** Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. *Phytomedicine.* 2002; 9: 224–31.
51. **Le Grimellec C, Friedlander G, el Yandouzi EH, et al.** Membrane fluidity and transport properties in epithelia. *Kidney Int.* 1992; 42: 825–36.
52. **Su L, Shen L, Clayburgh DR, et al.** Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. *Gastroenterology.* 2009; 136: 551–63.
53. **Shen L, Su L, Turner JR.** Mechanisms and functional implications of intestinal barrier defects. *Dig Dis.* 2009; 27: 443–9.
54. **Bouhet S, Hourcade E, Loiseau N, et al.** The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. *Toxicol Sci.* 2004; 77: 165–71.
55. **Groschwitz KR, Hogan SP.** Intestinal barrier function: molecular regulation and disease pathogenesis. *J Allergy Clin Immunol.* 2009; 124: 3–20; quiz 1–2.
56. **Park WJ, Park JW, Merrill AH, et al.** Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length. *Biochim Biophys Acta.* 2014; 1841: 1754–66.